Icosavax logo

Icosavax

Public Company
Seattle

Icosavax develops virus-like particle vaccines targeting respiratory viruses such as RSV, hMPV, and COVID-19. Its platform uses computational protein design and virus-like particle scaffolds to create experimental vaccines intended to be shelf-stable and advance to clinical trials.

Facts

HQ
Seattle
Sectors
Biotechnology, Vaccines, Life Sciences
Status
Public Company
Stage
Public
Members see funding amounts.
.

Is this your organization? Claim it

People